Survodutide
Also known as: BI 456906
Key Facts: Survodutide
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Phase 3 Clinical Trials
- Administration
- Subcutaneous injection weekly
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Human Trials
- Duration
- Long-term use expected
What to Expect
A dual GLP-1/glucagon receptor agonist in development for obesity and NASH. Combines appetite suppression with increased energy expenditure.
Mechanism of Action
Survodutide activates both GLP-1 receptors (appetite suppression, glucose control) and glucagon receptors (increased energy expenditure, reduced liver fat). The glucagon component adds metabolic benefits beyond pure GLP-1 agonists.
Research Summary
Phase 2 trials showed up to 19% weight loss at 46 weeks. Significant liver fat reduction makes it promising for NASH. Phase 3 trials ongoing for both obesity and NASH indications.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses from clinical trials
Doses from Studies
Titrated up to 4.8mg weekly
Various dose levels studied
Duration
Long-term use expected
Administration
Subcutaneous injection weekly
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (55-75%)
- ●Vomiting (41%)
- ●Diarrhea (49%)
- ●Constipation
- ●GI effects during dose escalation
- ●Currently in Phase 3 trials
References
Related Peptides
Peptides commonly compared with Survodutide or used in similar applications.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. Could provide injection-free alternative to semaglutide and tirzepatide.
Weight LossCagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog) in development. Aims to provide superior weight loss through dual mechanisms.
Weight LossCagrilintide
Clinical TrialsA long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Weight LossSemaglutide
FDAA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.
Weight LossWant updates on Survodutide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.